Herceptin acts as an anti-angiogenic cocktail
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Malignant tumours secrete factors that enable them to commandeer their own blood supply (angiogenesis), and blocking the action of these factors can inhibit tumour growth. But because tumours may become resistant to treatments that target individual angiogenic factors by switching over to other angiogenic molecules, a cocktail of multiple anti-angiogenic agents should be more effective. Here we show that herceptin, a monoclonal antibody against the cell-surface receptor HER2 (for human epidermal growth factor receptor-2; ref. 4), induces normalization and regression of the vasculature in an experimental human breast tumour that overexpresses HER2 in mice, and that it works by modulating the effects of different pro- and anti-angiogenic factors. As a single agent that acts against multiple targets, herceptin, or drugs like it, may offer a simple alternative to combination anti-angiogenic treatments.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Certain molecularly targeted agents, such as the anti-HER2 antibody trastuzumab, and metronomic chemotherapy can also induce vascular normalization via upregulation of thrombospondin expression28,116,117.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [116]
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Self-citationLeakage-Resistant Blood Vessels in Mice Transgenically Overexpressing Angiopoietin-1
Thurston, G., Suri, C., Smith, K., McClain, J., Sato, T. N., Yancopoulos, G. D., & McDonald, D. M. (1999) · Science · doi:10.1126/science.286.5449.2511 · Cited by 1,359
Tumor Induction of VEGF Promoter Activity in Stromal Cells
Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E.-C., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R. K., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81731-6 · Cited by 996
Self-citationThrombospondins as matricellular modulators of cell function
Bornstein, P. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12749 · Cited by 470
Allgayer, H., Babic, R., Gruetzner, K. U., Tarabichi, A., Schildberg, F. W., & Heiss, M. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2201 · Cited by 276
‘Accidental’ anti-angiogenic drugs
Kerbel, R. S., Viloria-Petit, A., Klement, G., & Rak, J. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00092-7 · Cited by 182
Angiogenic Heterogeneity: Regulation of Neoplastic Angiogenesis by the Organ Microenvironment
Fidler, I. J. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1040 · Cited by 109
Jain, R. K., & Carmeliet, P. (2001) · Scientific American · doi:10.1038/scientificamerican1201-38 · Cited by 94
Self-citation
Research works printed but not linked: 1
- Jain, R. K., Munn, L. L. & Fukumura, D. Nature Rev. Cancer (in the press).
Cited by
Items 101–200 of 622
Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer
Jain, R. K. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2346 · Cited by 165
Self-citationNF-κB-Mediated HER2 Overexpression inRadiation-Adaptive Resistance
Cao, N., Li, S., Wang, Z., Ahmed, K. M., Degnan, M. E., Fan, M., Dynlacht, J. R., & Li, J. J. (2009) · Radiation Research · doi:10.1667/rr1472.1 · Cited by 162
“HER2 is being studied extensively as a therapeutic target (14, 15 ).”
BackgroundImaging angiogenesis and the microenvironment
FUKUMURA, D., & JAIN, R. K. (2008) · APMIS · doi:10.1111/j.1600-0463.2008.01148.x · Cited by 162
Self-citationWen, X.-F., Yang, G., Mao, W., Thornton, A., Liu, J., Bast, R. C., & Le, X.-F. (2006) · Oncogene · doi:10.1038/sj.onc.1209685 · Cited by 159
Kodack, D. P., Chung, E., Yamashita, H., Incio, J., Duyverman, A. M. M. J., Song, Y., Farrar, C. T., Huang, Y., Ager, E., Kamoun, W., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216078109 · Cited by 153
“We have previously shown that trastuzumab alone can act as an antiangiogenic mixture in a leptomeningeal metastasis model of HER2-overexpressing breast cancer through a reduction in proangiogenic factors and an increase in an antiangiogenic factor (18).”
BackgroundSelf-citationInvasive breast cancer: correlation of dynamic MR features with prognostic factors
Szabó, B. K., Aspelin, P., Wiberg, M. K., Tot, T., & Boné, B. (2003) · European Radiology · doi:10.1007/s00330-003-2000-y · Cited by 153
Current approaches and future directions in the treatment of HER2-positive breast cancer
Hurvitz, S. A., Hu, Y., O’Brien, N., & Finn, R. S. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.04.008 · Cited by 150
Emerging Strategies for Treating Brain Metastases from Breast Cancer
Kodack, D. P., Askoxylakis, V., Ferraro, G. B., Fukumura, D., & Jain, R. K. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.01.001 · Cited by 159
Self-citationThe role of Neuregulin-1β/ErbB signaling in the heart
Pentassuglia, L., & Sawyer, D. B. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.08.015 · Cited by 162
du Manoir, J. M., Francia, G., Man, S., Mossoba, M. E., Medin, J. A., Viloria‐Petit, A., Hicklin, D. J., Emmenegger, U., & Kerbel, R. S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1109 · Cited by 151
Mechanisms of resistance to HER family targeting antibodies
Kruser, T. J., & Wheeler, D. L. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.01.009 · Cited by 157
Mechanisms of Disease: angiogenesis and the management of breast cancer
Banerjee, S. N., Dowsett, M., Ashworth, A., & Martin, L. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0905 · Cited by 156
Ricono, J. M., Huang, M., Barnes, L. A., Lau, S. K., Weis, S. M., Schlaepfer, D. D., Hanks, S. K., & Cheresh, D. A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3612 · Cited by 138
Oncogenic protein tyrosine kinases: Role of HER2/neu in tumor progression and therapy
M�nard, S., Casalini, P., Campiglio, M., Pupa, S. M., & Tagliabue, E. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4277-7 · Cited by 174
Espelin, C. W., Leonard, S. C., Geretti, E., Wickham, T. J., & Hendriks, B. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1518 · Cited by 137
HER2-Positive Breast Cancer: Current and Future Treatment Strategies
Engel, R. H., & Kaklamani, V. (2007) · Drugs · doi:10.2165/00003495-200767090-00006 · Cited by 157
Gura, T. (2002) · Nature · doi:10.1038/417584a · Cited by 149
Chakrabarty, A., Bhola, N. E., Sutton, C., Ghosh, R., Kuba, M. G., Dave, B., Chang, J. C., & Arteaga, C. L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2440 · Cited by 130
“Related to this finding, trastuzumab has been shown to act as an antiangiogenic agent by affecting different proangiogenic proteins including VEGF and angiopoietin (26).”
Hypoxic tumor microenvironment: Implications for cancer therapy
Roy, S., Kumaravel, S., Sharma, A., Duran, C. L., Bayless, K. J., & Chakraborty, S. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370220934038 · Cited by 141
In vitro three-dimensional tumor microenvironment models for anticancer drug discovery
Smalley, K. S., Lioni, M., Noma, K., Haass, N. K., & Herlyn, M. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.1.1 · Cited by 126
Plosker, G. L., & Keam, S. J. (2006) · Drugs · doi:10.2165/00003495-200666040-00005 · Cited by 127
Iivanainen, E., Nelimarkka, L., Elenius, V., Heikkinen, S.-M., Junttila, T. T., Sihombing, L., Sundvall, M., Määttä, J. A., Laine, V. J. O., Ylä-Herttuala, S., et al. (2003) · The FASEB Journal · doi:10.1096/fj.02-0939com · Cited by 125
Tumor angiogenesis and novel antiangiogenic strategies
Gordon, M. S., Mendelson, D. S., & Kato, G. (2010) · International Journal of Cancer · doi:10.1002/ijc.25026 · Cited by 136
Tumor‐vascular interactions and tumor dormancy
Naumov, G. N., Folkman, J., Straume, O., & Akslen, L. A. (2008) · Apmis · doi:10.1111/j.1600-0463.2008.01213.x · Cited by 140
Developmental and pathological angiogenesis in the central nervous system
Vallon, M., Chang, J., Zhang, H., & Kuo, C. J. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1625-0 · Cited by 124
Are tumours angiogenesis‐dependent?
Verheul, H. M. W., Voest, E. E., & Schlingemann, R. O. (2003) · The Journal of Pathology · doi:10.1002/path.1473 · Cited by 143
Cilliers, C., Guo, H., Liao, J., Christodolu, N., & Thurber, G. M. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9940-z · Cited by 125
Development of novel therapeutic strategies that target HIF-1
Semenza, G. L. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.2.267 · Cited by 120
Orlando, L., Cardillo, A., Ghisini, R., Rocca, A., Balduzzi, A., Torrisi, R., Peruzzotti, G., Goldhirsch, A., Pietri, E., & Colleoni, M. A. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-225 · Cited by 119
Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
Fiszman, G. L., & Jasnis, M. A. (2011) · International Journal of Breast Cancer · doi:10.4061/2011/352182 · Cited by 131
Aberrant vascular architecture in tumors and its importance in drug-based therapies
Munn, L. L. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02686-2 · Cited by 139
Hurvitz, S. A., Betting, D. J., Stern, H. M., Quinaux, E., Stinson, J., Seshagiri, S., Zhao, Y., Buyse, M., Mackey, J., Driga, A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2294 · Cited by 115
“shedding, decreased angiogenesis, and inhibition of DNA repair (7, 8).”
Stimulated γδ T Cells Increase the In Vivo Efficacy of Trastuzumab in HER-2+ Breast Cancer
Capietto, A.-H., Martinet, L., & Fournié, J. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100681 · Cited by 124
Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model.
Calsteren, K. V., Verbesselt, R., Devlieger, R., Catte, L. D., Chai, D. C., Bree, R. V., Heyns, L., Beijnen, J. H., Demarsin, S., de Bruijn, E. A., et al. (2010) · PubMed · doi:10.1111/igc.0b013e3181fb18c8 · Cited by 116
O’Shaughnessy, J., Vukelja, S., Marsland, T., Kimmel, G. T., Ratnam, S., & Pippen, J. (2004) · Clinical Breast Cancer · doi:10.3816/cbc.2004.n.019 · Cited by 114
Yang, G., Cai, K. Q., Thompson-Lanza, J. A., Bast, R. C., & Liu, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311153200 · Cited by 114
Tortora, G., Ciardiello, F., & Gasparini, G. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1161 · Cited by 116
Evolving novel anti-HER2 strategies
Jones, K. L., & Buzdar, A. U. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70315-8 · Cited by 126
Garnock-Jones, K. P., Keating, G. M., & Scott, L. J. (2010) · Drugs · doi:10.2165/11203700-000000000-00000 · Cited by 130
Köninki, K., Barok, M., Tanner, M., Staff, S. M., Pitkänen, J., Hemmilä, P., Ilvesaro, J. M., & Isola, J. J. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.02.002 · Cited by 117
Graphene quantum dot-based theranostic agents for active targeting of breast cancer
Ko, N. R., Nafiujjaman, M., Lee, J. S., Lim, H.-N., Lee, Y.-K., & Kwon, I. K. (2017) · RSC Advances · doi:10.1039/c6ra25949a · Cited by 114
Klos, K. S., Zhou, X., Lee, S., Zhang, L., Yang, W., Nagata, Y., & Yu, D. (2003) · Cancer · doi:10.1002/cncr.11656 · Cited by 139
Engineering therapeutic monoclonal antibodies
Liu, X., Pop, L. M., & Vitetta, E. S. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00601.x · Cited by 130
Unraveling the Biologic and Clinical Complexities of HER2
Park, J. W., Neve, R. M., Szöllõsi, J., & Benz, C. C. (2008) · Clinical Breast Cancer · doi:10.3816/cbc.2008.n.047 · Cited by 123
Recombinant antibodies for cancer diagnosis and therapy
Souriau, C., & Hudson, P. J. (2003) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.3.2.305 · Cited by 114
Trastuzumab Emtansine (T-DM1): A Novel Agent for Targeting HER2+ Breast Cancer
Burris, H. A., Tibbitts, J., Holden, S. N., Sliwkowski, M. X., & Phillips, G. D. L. (2011) · Clinical Breast Cancer · doi:10.1016/j.clbc.2011.03.018 · Cited by 123
Karagiannis, P., Singer, J., Hunt, J., Gan, S. K. E., Rudman, S. M., Mechtcheriakova, D., Knittelfelder, R., Daniels, T. R., Hobson, P. S., Beavil, A. J., et al. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0607-1 · Cited by 106
Li, Y. M., Zhou, B. P., Deng, J., Pan, Y., Hay, N., & Hung, M.-C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1284 · Cited by 106
Pastuskovas, C. V., Mundo, E. E., Williams, S. P., Nayak, T. K., Ho, J., Ulufatu, S., Clark, S., Ross, S., Cheng, E., Parsons-Reponte, K., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0742-t · Cited by 103
Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer
Najjar, M. K., Manore, S. G., Regua, A. T., & Lo, H. (2022) · Genes · doi:10.3390/genes13112065 · Cited by 124
Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer
Yeon, C. H., & Pegram, M. D. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-2899-8 · Cited by 111
Schäller, G., Fuchs, I. B., Gonsch, T., Weber, J., Kleine-Tebbe, A., Klare, P., Hindenburg, H.-J., Lakner, V., Hinke, A., & Bangemann, N. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6826 · Cited by 99
Tóth, G., Szöőr, Á., Simon, L., Yarden, Y., Szöllõsi, J., & Vereb, G. (2016) · mAbs · doi:10.1080/19420862.2016.1204503 · Cited by 94
Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies
Comunanza, V., & Bussolino, F. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00101 · Cited by 111
Duda, D. G., Willett, C. G., Ancukiewicz, M., Tomaso, E., Shah, M., Czito, B. G., Bentley, R., Poleski, M., Lauwers, G. Y., Carroll, M., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0029 · Cited by 94
Self-citationHuang, H., Zhang, C., Wang, X., Shao, J., Chen, C., Li, H., Ju, C.-M., He, J., Gu, H., & Xia, D. (2020) · Nano Letters · doi:10.1021/acs.nanolett.0c00650 · Cited by 93
EGFR Family Members’ Regulation of Autophagy Is at a Crossroads of Cell Survival and Death in Cancer
Henson, E. S., Chen, Y., & Gibson, S. B. (2017) · Cancers · doi:10.3390/cancers9040027 · Cited by 100
Targeting hypoxia tolerance in cancer
Wouters, B. G., van den Beucken, T., Magagnin, M. G., Lambin, P., & Koumenis, C. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2003.12.004 · Cited by 96
CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
Rivera, Z. S., Ferrone, S., Wang, X., Jube, S., Yang, H., Pass, H. I., Kanodia, S., Gaudino, G., & Carbone, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0628 · Cited by 94
Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer
Nahta, R. (2012) · ISRN Oncology · doi:10.5402/2012/428062 · Cited by 108
HER2 as a target for breast cancer therapy
Tagliabue, E., Balsari, A., Campiglio, M., & Pupa, S. M. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712591003689972 · Cited by 95
Antitumor activity of HER-2 inhibitors
Rabindran, S. K. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.11.015 · Cited by 96
Marcucci, F., & Corti, A. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.09.007 · Cited by 94
Adjuvant Trastuzumab Therapy for HER2-Positive Breast Cancer
Jahanzeb, M. (2008) · Clinical Breast Cancer · doi:10.3816/cbc.2008.n.037 · Cited by 89
Gene-Engineered T Cells as a Superior Adjuvant Therapy for Metastatic Cancer
Kershaw, M. H., Jackson, J. T., Haynes, N. M., Teng, M. W. L., Moeller, M., Hayakawa, Y., Street, S. E., Cameron, R., Tanner, J. E., Trapani, J. A., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.3.2143 · Cited by 84
Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments
Barros, F., Powe, D. G., Ellis, I. O., & Green, A. R. (2010) · Histopathology · doi:10.1111/j.1365-2559.2010.03494.x · Cited by 99
Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment
Askoxylakis, V., Ferraro, G. B., Kodack, D. P., Badeaux, M. D., Shankaraiah, R. C., Seano, G., Kloepper, J., Vardam, T. D., Martin, J. D., Naxerova, K., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv313 · Cited by 87
Self-citationLauriola, M., Enuka, Y., Zeisel, A., D’Uva, G., Roth, L. E., Sevilla-Sharon, M., Lindzen, M., Sharma, K., Nevo, N., Feldman, M. E., et al. (2014) · Nature Communications · doi:10.1038/ncomms6073 · Cited by 86
Warburton, C., Dragowska, W. H., Gelmon, K., Chia, S., Yan, H., Masin, D., Denyssevych, T., Wallis, A. E., & Bally, M. B. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0244 · Cited by 82
Henjes, F., Bender, C., von der Heyde, S., Braun, L., Mannsperger, H., Schmidt, C., Wiemann, S., Hasmann, M., Aulmann, S., Beißbarth, T., et al. (2012) · Oncogenesis · doi:10.1038/oncsis.2012.16 · Cited by 83
Pietras, R. J. (2003) · The Breast Journal · doi:10.1046/j.1524-4741.2003.09510.x · Cited by 85
Ebos, J. M. L., Tran, J., Master, Z., Dumont, D., Melo, J. V., Buchdunger, E., & Kerbel, R. S. (2002) · PubMed · Cited by 80
Monoclonal Antibody-Based Targeted Therapy in Breast Cancer: Current Status and Future Directions
Bernard-Marty, C., Lebrun, F., Awada, A. H., & Piccart, M. J. (2006) · Drugs · doi:10.2165/00003495-200666120-00004 · Cited by 90
Wong, A. L. A., & Lee, S.-C. (2012) · International Journal of Breast Cancer · doi:10.1155/2012/415170 · Cited by 77
Chung, A. P., Cui, X., Audeh, W., & Giuliano, A. E. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.04.001 · Cited by 84
Brufsky, A. (2010) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e318191bfb0 · Cited by 81
Campbell, N., Greenaway, J. B., Henkin, J., Moorehead, R. A., & Petrik, J. (2010) · Neoplasia · doi:10.1593/neo.91880 · Cited by 76
Therapeutic approaches for HER2-positive brain metastases: Circumventing the blood–brain barrier
Mehta, A. I., Brufsky, A., & Sampson, J. H. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.05.006 · Cited by 75
Modulation of cell death in the tumor microenvironment
Wouters, B. G., Koritzinsky, M., Chiu, R. K., Theys, J., Buijsen, J., & Lambin, P. (2003) · Seminars in Radiation Oncology · doi:10.1053/srao.2003.50004 · Cited by 84
Mechanisms of Trastuzumab Resistance and Their Clinical Implications
Lan, K., Lu, C., & Yu, D. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1339.026 · Cited by 75
Benlimame, N., Alaoui-Jamali, M., & Davis, M. B. (2009) · Cited by 80
Vivekanandhan, S., & Knutson, K. L. (2022) · Cancers · doi:10.3390/cancers14205115 · Cited by 88
Liao, S., Liu, J., Lin, P., Shi, T., Jain, R. K., & Xu, L. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2429 · Cited by 73
Self-citationAntiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment
Chen, W., Shen, L., Jiang, J., Zhang, L., Zhang, Z., Pan, J., Ni, C., & Chen, Z. (2021) · Biomarker Research · doi:10.1186/s40364-021-00312-w · Cited by 79
ErbB-directed immunotherapy: Antibodies in current practice and promising new agents
Friedländer, E., Barok, M., Szöllõsi, J., & Vereb, G. (2008) · Immunology Letters · doi:10.1016/j.imlet.2007.12.001 · Cited by 79
Oncogenes and tumor angiogenesis
Rak, J. W., & Yu, J. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.09.014 · Cited by 90
Fokas, E., McKenna, W. G., & Muschel, R. J. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9394-4 · Cited by 75
Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls
Leyland-Jones, B. R., & Smith, B. R. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70297-7 · Cited by 75
Stemming Resistance to HER-2 Targeted Therapy
Bedard, P. L., Cardoso, F., & Piccart, M. J. (2009) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-009-9116-x · Cited by 77
Kim, W., & Lee, H. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07177.x · Cited by 72
Viloria‐Petit, A., Miquerol, L., Yu, J. L., Gertsenstein, M., Sheehan, C., May, L., Henkin, J., Lobe, C., Nagy, A., Kerbel, R. S., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg408 · Cited by 71
Metronomic chemotherapy and drug repurposing: A paradigm shift in oncology
Jan, N., Sofi, S., Qayoom, H., Shabir, A., Haq, B. U., Macha, M. A., Almilaibary, A., & Mir, M. A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24670 · Cited by 78
HER2 breast cancer therapies: a review
Modi, S., & Murphy, C. G. (2009) · Biologics · doi:10.2147/btt.2009.3250 · Cited by 87
Recent advances in novel targeted therapies for HER2-positive breast cancer
Murphy, C. G., & Morris, P. G. (2012) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328352d292 · Cited by 72
Modulation of MicroRNA-194 and Cell Migration by HER2-Targeting Trastuzumab in Breast Cancer
Le, X., Almeida, M. I., Mao, W., Spizzo, R., Rossi, S., Nicoloso, M. S., Zhang, S., Wu, Y., Călin, G. A., & Bast, R. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041170 · Cited by 69
Kuerer, H. M., Buzdar, A. U., Mittendorf, E. A., Esteva, F. J., Lucci, A., Vence, L. M., Radvanyi, L. G., Meric‐Bernstam, F., Hunt, K. K., & Symmans, W. F. (2010) · Cancer · doi:10.1002/cncr.25399 · Cited by 67
Antonelli, A., Bocci, G., La Motta, C., Ferrari, S. M., Fallahi, P., Fioravanti, A., Sartini, S., Minuto, M., Piaggi, S., Corti, A., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1905 · Cited by 66
Carvalho, S., Levi‐Schaffer, F., Sela, M., & Yarden, Y. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13450 · Cited by 72
Promises and pitfalls of anti-angiogenic therapy in clinical trials
McCarty, M. F., Liu, W., Fan, F., Parikh, A. A., Reimuth, N., Stoeltzing, O., & Ellis, L. M. (2003) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(03)00002-9 · Cited by 65
Monoclonal Antibodies, Small Molecules, and Vaccines in the Treatment of Breast Cancer
Esteva, F. J. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_3-4 · Cited by 64
Metadata
- Authors
- Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Nature
- Published
- 2002-03
- Volume
- 416
- Issue
- 6878
- Pages
- 279-280
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2034801324
- Cited by
- 623
- References
- 11
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 26 · 2023: 10 · 2022: 14 · 2021: 12 · 2020: 18 · 2019: 12 · 2018: 20 · 2017: 23 · 2016: 18 · 2015: 24 · 2014: 27 · 2013: 30 · 2012: 35
- FWCI
- 12.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (P01CA080124)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- trastuzumab, anti-angiogenic therapy, HER2, human epidermal growth factor receptor 2, tumor angiogenesis, tumor regression, combination therapy, breast cancer, monoclonal antibodies, tumor resistance
- MeSH terms
- Trastuzumab, Animals, Antibodies, Monoclonal, Humans, Lymphokines, Mammary Neoplasms, Experimental, Neovascularization, Pathologic, Signal Transduction, Gene Expression, Endothelial Growth Factors, Mice, SCID, Genes, erbB-2, Angiogenesis Inhibitors, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Mice, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.